Precision BioSciences, Inc. (NASDAQ:DTIL) CFO Sells $63,163.02 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) CFO John Alexander Kelly sold 14,827 shares of the business's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.26, for a total transaction of $63,163.02. Following the sale, the chief financial officer directly owned 73,485 shares in the company, valued at $313,046.10. The trade was a 16.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Precision BioSciences Stock Down 7.9%

DTIL stock traded down $0.38 on Friday, hitting $4.45. 188,179 shares of the company's stock were exchanged, compared to its average volume of 226,762. The stock has a market cap of $49.35 million, a P/E ratio of -2.21 and a beta of 1.43. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.62 and a current ratio of 6.62. The firm has a 50 day moving average price of $4.80 and a two-hundred day moving average price of $4.93. Precision BioSciences, Inc. has a 12-month low of $3.61 and a 12-month high of $11.09.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.43) by ($1.78). Precision BioSciences had a negative net margin of 42.99% and a negative return on equity of 69.26%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $5.00 million. As a group, equities research analysts expect that Precision BioSciences, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $60.00 target price on shares of Precision BioSciences in a research note on Wednesday, May 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in Precision BioSciences during the fourth quarter worth about $146,000. Citadel Advisors LLC grew its position in shares of Precision BioSciences by 58.0% in the 4th quarter. Citadel Advisors LLC now owns 153,675 shares of the company's stock valued at $586,000 after buying an additional 56,400 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Precision BioSciences during the fourth quarter worth about $179,000. Samalin Investment Counsel LLC acquired a new stake in shares of Precision BioSciences in the fourth quarter valued at approximately $59,000. Finally, Commonwealth Equity Services LLC purchased a new position in Precision BioSciences during the 4th quarter worth $48,000. Institutional investors and hedge funds own 37.99% of the company's stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.